Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2009-05-20 Management Reports
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
Managing Director`s Presentation 4 pages ?Kb
Management Reports Classification · 95% confidence The document is a Managing Director's presentation discussing the company's 2008 financial results, business updates, and strategic outlook. It includes detailed financial performance data such as profit increases, earnings per share, cash flow, and capital raising activities. The presentation also covers operational highlights, market development, regulatory interactions, and future plans. The content is comprehensive and includes substantive financial data and management commentary, typical of a Management Reports (MDA) document rather than a brief earnings release or investor presentation. It is not a full Annual Report (10-K) but rather a detailed management discussion and analysis of the financial results and business strategy. Therefore, the appropriate classification is Management Reports (MDA).
2009-05-20 English
Chairman`s Address 2 pages ?Kb
AGM Information Classification · 95% confidence The document is titled 'Chairman’s Address' and is dated 21 May 2009, coinciding with an Annual General Meeting (AGM) of Cyclopharm Limited. It includes introductory remarks by the Chairman, mentions the presence of directors and auditors, and discusses company performance, strategy, and shareholder matters. The content is typical of a speech or presentation given at an AGM rather than a full annual report or financial statement. The document length is 4364 characters, which is relatively short and consistent with an AGM presentation or address. There is no detailed financial data or comprehensive report content, so it is not an Annual Report (10-K) or Interim Report (IR). The focus on welcoming attendees, declaring a quorum, and discussing company highlights aligns with AGM Information. Therefore, the document is best classified as AGM Information (AGM-R).
2009-05-20 English
Results of Meeting 2 pages ?Kb
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Results of Annual General Meeting on 21 May 2009' and provides detailed voting results for multiple resolutions passed at the AGM, including items such as the Remuneration Report, Re-Election of Directors, Share Buy-back, and Approval of Takeover Bids. The content focuses on the official announcement of voting outcomes rather than the meeting materials or the full AGM report. The document length is 2680 characters, which is relatively short and consistent with a voting results announcement. Therefore, this document fits the category of 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2009-05-20 English
Company Update 3 pages ?Kb
Management Reports Classification · 95% confidence The document is a company update dated 28 April 2009, providing detailed information on the company's progress, including operational updates, product development, regulatory submissions (FDA New Drug Application), market information, and legal action. It is addressed to shareholders and includes a message from the Managing Director. The content is narrative and strategic rather than a formal financial report or regulatory filing. It does not contain financial statements or detailed financial data typical of Annual Reports (10-K), Interim Reports (IR), or Earnings Releases (ER). It also does not fit categories like Board/Management changes, Capital updates, or Legal Proceedings reports as the legal action mentioned is brief and part of a broader company update. The document is longer than 5,000 characters and provides substantive company progress information, which aligns best with a Management Reports (MDA) filing, where management explains business trends, progress, and outlook to shareholders.
2009-04-27 English
Notice of General Meeting/Proxy Form 27 pages ?Kb
AGM Information Classification · 95% confidence The document is titled 'Cyclopharm Limited Notice of Annual General Meeting and Explanatory Statement' and includes detailed information about the upcoming AGM, including the date, location, agenda items such as financial statements, remuneration report, director elections, share buy-back, and takeover bid approvals. It also contains proxy voting instructions and explanatory notes for each resolution. The content is typical of a Notice of Meeting and Explanatory Statement sent to shareholders prior to an AGM to inform them and solicit votes. It is not the actual Annual Report or financial statements themselves, nor is it a voting results announcement or proxy solicitation document alone. Therefore, the document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting.
2009-04-19 English
Annual Report to shareholders 80 pages ?Kb
Annual Report Classification · 100% confidence The document is titled 'Cyclopharm Limited Annual Report 2008' and contains detailed sections typical of an annual report, including Financial Highlights, Chairman’s Letter, Managing Director’s Review, Directors’ Report, Auditor’s Independence Declaration, Corporate Governance, Income Statement, Balance Sheet, Cash Flow Statement, Statement of Changes in Equity, Notes, Directors’ Declaration, Independent Audit Report, and ASX Additional Information. The content includes comprehensive financial data, management discussion, and audited financial statements for the full fiscal year ending 31 December 2008. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or summary. Therefore, this document fits the definition of an Annual Report (10-K). FY 2008
2009-03-25 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.